Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Sell
50
MDT Quote, Financials, Valuation and Earnings
Last price:
$88.86
Seasonality move
:
4.65%
Day range:
$88.21 - $89.59
52-week range:
$75.96 - $96.25
Dividend yield:
3.16%
P/E ratio:
26.90x
P/S ratio:
3.46x
P/B ratio:
2.30x
Volume:
6.9M
Avg. volume:
8M
1-year change:
1.69%
Market cap:
$113.5B
Revenue:
$32.4B
EPS (TTM):
$3.29
Analysts' Opinion
-
Consensus RatingMedtronic PLC has received a consensus rating of Hold. The company's average rating is a Hold based on 11 Buy ratings, 14 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $97.05, Medtronic PLC has an estimated upside of 9.68% from its current price of $88.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $85.00 representing 3.94% downside risk from its current price of $88.49.
Fair Value
-
According to the consensus of 26 analysts, Medtronic PLC has 9.68% upside to fair value with a price target of $97.05 per share.
MDT vs. S&P 500
-
Over the past 5 trading days, Medtronic PLC has overperformed the S&P 500 by 1.76% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Medtronic PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Medtronic PLC has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Medtronic PLC reported revenues of $8.3B.
Earnings Growth
-
Medtronic PLC has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Medtronic PLC reported earnings per share of $1.01.
Enterprise value:
132.4B
EV / Invested capital:
1.74x
Price / LTM sales:
3.46x
EV / EBIT:
22.14x
EV / Revenue:
3.99x
PEG ratio (5yr expected):
5.63x
EV / Free cash flow:
24.21x
Price / Operating cash flow:
21.01x
Enterprise value / EBITDA:
15.29x
Gross Profit (TTM):
$21.7B
Return On Assets:
4.73%
Net Income Margin (TTM):
12.83%
Return On Equity:
8.56%
Return On Invested Capital:
5.58%
Operating Margin:
20.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Income Statement | ||||||
| Revenue | $30.8B | $32.3B | $33.2B | $8.1B | $8.3B | |
| Gross Profit | $20.4B | $21.2B | $21.7B | $5.3B | $5.5B | |
| Operating Income | $5.7B | $6.1B | $6B | $1.5B | $1.7B | |
| EBITDA | $8.7B | $8.9B | $8.7B | $2.3B | $2.4B | |
| Diluted EPS | $3.04 | $3.14 | $3.29 | $0.99 | $1.01 | |
| Period Ending | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 | 2025-01-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.3B | $23.3B | $25.4B | $22.5B | $22.5B | |
| Total Assets | $97.3B | $91.8B | $94.1B | $90.8B | $90B | |
| Current Liabilities | $12.5B | $8.9B | $14.4B | $9.8B | $11.8B | |
| Total Liabilities | $46.3B | $39.1B | $42.5B | $38.8B | $40.4B | |
| Total Equity | $50.9B | $52.7B | $51.6B | $52B | $49.6B | |
| Total Debt | $30.3B | $25.1B | $28.1B | $25.1B | $26.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $5.6B | $6.5B | $7.3B | $2.5B | $2.6B | |
| Cash From Investing | -$2.7B | -$2.1B | -$2.1B | -$707M | -$843M | |
| Cash From Financing | -$2B | -$7B | -$5.4B | -$1.5B | -$1.8B | |
| Free Cash Flow | $4.2B | $4.9B | $5.5B | $2.1B | $2.1B | |
MDT
Sector
Market Cap
$113.5B
$35.9M
Price % of 52-Week High
91.94%
42.55%
Dividend Yield
3.16%
0%
Shareholder Yield
6.34%
-1.03%
1-Year Price Total Return
1.69%
-44.4%
Beta (5-Year)
0.794
0.746
Dividend yield:
3.16%
Annualized payout:
$2.76
Payout ratio:
84.62%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$89.03
200-day SMA
Buy
Level
$86.20
Bollinger Bands (100)
Buy
Level
83.3 - 91.66
Chaikin Money Flow
Buy
Level
730.9M
20-day SMA
Sell
Level
$91.29
Relative Strength Index (RSI14)
Sell
Level
42.78
ADX Line
Sell
Level
19.67
Williams %R
Neutral
Level
-76.9684
50-day SMA
Sell
Level
$90.74
MACD (12, 26)
Sell
Level
-0.57
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
449.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.781)
Buy
CA Score
(Annual)
Level (0.2368)
Buy
Beneish M-Score
(Annual)
Level (-2.6317)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-2.0959)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Stock Forecast FAQ
In the current month, MDT has received 11 Buy ratings 14 Hold ratings, and 1 Sell ratings. The MDT average analyst price target in the past 3 months is $97.05.
-
Where Will Medtronic PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Medtronic PLC share price will rise to $97.05 per share over the next 12 months.
-
What Do Analysts Say About Medtronic PLC?
Analysts are divided on their view about Medtronic PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Medtronic PLC is a Sell and believe this share price will drop from its current level to $85.00.
-
What Is Medtronic PLC's Price Target?
The price target for Medtronic PLC over the next 1-year time period is forecast to be $97.05 according to 26 Wall Street analysts, 11 of them rate the stock a Buy, 1 rates the stock a Sell, and 14 analysts rate the stock a Hold.
-
Is MDT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Medtronic PLC is a Hold. 14 of 26 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MDT?
You can purchase shares of Medtronic PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Medtronic PLC shares.
-
What Is The Medtronic PLC Share Price Today?
Medtronic PLC was last trading at $88.86 per share. This represents the most recent stock quote for Medtronic PLC. Yesterday, Medtronic PLC closed at $88.49 per share.
-
How To Buy Medtronic PLC Stock Online?
In order to purchase Medtronic PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
